Focused Research Areas

Our team advances treatments for sports injuries using stem cell therapies that promote faster recovery and tissue repair. We also develop innovative approaches to musculoskeletal regeneration to restore function and reduce chronic pain.


The Cognify Clinical Trial Program is a nationwide, FDA-authorized Expanded Access trial for TB-006 — an investigational monoclonal antibody targeting galectin-3, a critical immune molecule at the crossroads of neuroinflammation and protein misfolding in Alzheimer’s disease.


Unlike traditional trials, Cognify is structured to allow eligible clinics to provide TB-006 under compassionate use, offering a treatment



At Promethium Research Center, we offer stem cell treatments for sports injuries and lead focused research in Alzheimer’s disease, guided by science and patient-centered care.

Dr. Alberto Rivera, MD, FAAPMR, ABPM, ABPMR, is an internationally recognized speaker in stem cell science, sharing his clinical expertise at scientific conferences and professional forums worldwide. He is also the author of Primal Fuel: The Ultimate Guide. His lectures focus on regenerative medicine and the application of stem cell technologies in sports-related musculoskeletal injuries, emphasizing scientific rigor, clinical experience, and responsible use of regenerative approaches.

Patient Testimonial

Participating in the TB006 research study gave us confidence that we were contributing to meaningful scientific progress. The research team was professional, attentive, and transparent throughout the process

Maria Thompson

Dr. Rivera has been actively working with stem cell technologies since 2013, with a strong focus on their application in sports injuries and musculoskeletal regeneration. His work in this area centers on cellular repair, tissue recovery, and biologically driven approaches to injury management for athletes and physically active individuals, grounded in scientific rigor and translational relevance.

Why Should I Participate in the Cognify Trial? 

  • The study medication is called TB006, which is a novel monoclonal antibody therapy targeting Galectin-3; a protein implicated in neuroinflammation and cognitive decline in Alzheimer’s disease. TB006 is designed to neutralize this protein’s damaging effects, with the goal of slowing or halting disease progression by reducing brain inflammation and improving neuronal survival.

  • You will be treated by a doctor at a nationally renowned medical center.

  • You will be helping to find an effective treatment for Alzheimer’s and dementia for patients like you. 


Under the scientific leadership of Dr. Al Rivera, our work advances stem cell applications and dedicated research in Alzheimer’s disease.

Led by Dr. Alberto Rivera, MD, our work reflects his long-standing expertise in stem cell science and Alzheimer’s research. Since 2013, Dr. Rivera has provided stem cell–based services focused on sports injuries and musculoskeletal recovery. He also leads a dedicated Alzheimer’s research center conducting an FDA-approved Phase 2 study.